45
Participants
Start Date
April 30, 2009
Primary Completion Date
June 30, 2011
Study Completion Date
June 30, 2012
Lenalidomide
5 mg, 10 mg, 25 mg, and/or 50 mg of lenalidomide administered PO from day 8 to Day 28 of each cycle
Azacitidine
75 mg/m2 Azacitidine administered intravenously (IV) or subcutaneously (SC) for days 1 to 7 of each cycle
Stanford University School of Medicine, Stanford
Collaborators (1)
Celgene Corporation
INDUSTRY
Stanford University
OTHER